Consulting Services
For Investors
- Lucid Diligence Briefs
- Venture Capital
Case Studies
Insights
- Conference Previews
- Conference Social Media Reports
BioPharma and Tech News
LucidSearch
QuickAnswers

Contact Us

Search

MannKind

Respiratory

Respiratory Video Recap—November 14, 2025

This respiratory video recap spans late-stage trial launches, regulatory…

Endocrinology

Endocrinology Today — October 21, 2025

Endocrinology news this week covers major developments, updates, launches and…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Rare Disease News
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Lucid Diligence Brief: Neurable raises $35M Series A to scale brain-signal AI
Neuroscience 2025 Review: Disease Modification Meets Deliverability
Women’s Health 2025 Review: From Fragmented Care to Scaled Platforms
Obesity Review 2025: The Rise of Oralization, the Muscle Question, and a New Era of Access Pressure
Lucid Diligence Brief: Truemed $34m Series A to scale payment integration platform

Tags

advanced therapies AI in dermatology American Society of Hematology AMWC 2025 antibody design bioinformatics Biopharma investment brain aging cancer CDKL5 deficiency disorder corporate venture capital Cycle Pharma EAS 2025 Elranatamab EpiEndo Pharmaceuticals ESMO 2021 gene editing gene therapy approval Heartnote hematology hepatitis D Ischemic heart disease Mechanical prosthetic valve thrombosis Mental health therapeutics Minimally invasive surgery Mucosal immunity muscarinic myocardial infarction NFTs in healthcare Nipah virus infection non viral vectors noom Palbociclib Paroxysmal supraventricular tachycardia pharma prevention protein misfolding Psychiatric disorders respiratory science retinal ai SCTbio Sema4 skin conditions Triceps triple agonist

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Lucid Diligence Brief: Neurable raises $35M Series A to scale brain-signal AI
Neuroscience 2025 Review: Disease Modification Meets Deliverability
Women’s Health 2025 Review: From Fragmented Care to Scaled Platforms
Obesity Review 2025: The Rise of Oralization, the Muscle Question, and a New Era of Access Pressure
Lucid Diligence Brief: Truemed $34m Series A to scale payment integration platform

TAGS

advanced therapies AI in dermatology American Society of Hematology AMWC 2025 antibody design bioinformatics Biopharma investment brain aging cancer CDKL5 deficiency disorder corporate venture capital Cycle Pharma EAS 2025 Elranatamab EpiEndo Pharmaceuticals ESMO 2021 gene editing gene therapy approval Heartnote hematology hepatitis D Ischemic heart disease Mechanical prosthetic valve thrombosis Mental health therapeutics Minimally invasive surgery Mucosal immunity muscarinic myocardial infarction NFTs in healthcare Nipah virus infection non viral vectors noom Palbociclib Paroxysmal supraventricular tachycardia pharma prevention protein misfolding Psychiatric disorders respiratory science retinal ai SCTbio Sema4 skin conditions Triceps triple agonist

Consulting Services
For Investors
- Lucid Diligence Briefs
- Venture Capital
Case Studies
Insights
- Conference Previews
- Conference Social Media Reports
BioPharma and Tech News
LucidSearch
QuickAnswers

© 2025 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy